INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 179 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2016. The put-call ratio across all filers is 0.73 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $602,000 | -30.1% | 12,560 | -8.1% | 0.01% | -42.9% |
| Q1 2020 | $861,000 | -42.3% | 13,660 | +8.8% | 0.01% | -6.7% |
| Q4 2019 | $1,491,000 | +78.8% | 12,560 | 0.0% | 0.02% | +66.7% |
| Q3 2019 | $834,000 | -18.6% | 12,560 | -2.3% | 0.01% | -18.2% |
| Q2 2019 | $1,024,000 | +509.5% | 12,860 | +757.3% | 0.01% | +450.0% |
| Q1 2019 | $168,000 | +479.3% | 1,500 | +200.0% | 0.00% | – |
| Q4 2017 | $29,000 | 0.0% | 500 | 0.0% | 0.00% | – |
| Q3 2017 | $29,000 | -52.5% | 500 | 0.0% | 0.00% | -100.0% |
| Q2 2017 | $61,000 | +7.0% | 500 | 0.0% | 0.00% | – |
| Q1 2017 | $57,000 | +5600.0% | 500 | +24900.0% | 0.00% | – |
| Q3 2016 | $1,000 | 0.0% | 2 | 0.0% | 0.00% | – |
| Q2 2016 | $1,000 | 0.0% | 2 | -50.0% | 0.00% | – |
| Q1 2016 | $1,000 | 0.0% | 4 | +100.0% | 0.00% | – |
| Q4 2015 | $1,000 | – | 2 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $14,787,000 | 2.73% |
| DeepCurrents Investment Group LLC | 416,800 | $9,620,000 | 0.33% |
| DUALITY ADVISERS, LP | 105,668 | $2,439,000 | 0.21% |
| EULAV Asset Management | 335,000 | $7,732,000 | 0.21% |
| Virtus ETF Advisers LLC | 19,375 | $447,000 | 0.19% |
| Hennion & Walsh Asset Management, Inc. | 135,214 | $3,121,000 | 0.19% |
| PDT Partners, LLC | 110,592 | $2,552,000 | 0.18% |
| KETTLE HILL CAPITAL MANAGEMENT, LLC | 70,256 | $1,622,000 | 0.16% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $3,896,000 | 0.12% |
| WOODWARD DIVERSIFIED CAPITAL, LLC | 8,939 | $206,000 | 0.12% |